Benchmark Reiterates Buy Rating, $7.50 PT for CryoLife

In a report published earlier today, Benchmark reiterated its Buy rating and $7.50 price target for CryoLife, Inc.

. Benchmark went on to say “CryoLife's strategy is to generate substantial long term value by strengthening and leveraging market leading sales forces in cardiac and vascular surgery. There are relatively few mid-sized medical device distribution companies in this niche, which may present an opportunity for CryoLife to become a partner of choice for innovative companies approaching commercialization.” CryoLife, Inc. closed on Friday at $4.83.